Net profit of Astrazeneca Pharma India declined 53.97% to Rs 5.80 crore in the quarter ended June 2017 as against Rs 12.60 crore during the previous quarter ended June 2016. Sales declined 8.64% to Rs 127.48 crore in the quarter ended June 2017 as against Rs 139.54 crore during the previous quarter ended June 2016.

Powered by Capital Market - Live News

Astrazeneca Pharma India announced that at the Board meeting of the Company held on 08 August 2017, the Board considered and approved inter alia the following business:

1. Ian John Parish has been appointed as director (non-executive) on the Board of Directors of the company in the casual vacancy caused by the resignation of Ian Brimicombe, who resigned as director w.e.f 31 May 2017.

2. The Board has approved the convening of the 38th Annual General Meeting of the Company on 13 September 2017.

Powered by Capital Market - Live News

Astrazeneca Pharma India announced that it has received a letter from AstraZeneca UK to further extend the date of withdrawal of Meronem from 31 July 2017 to 31 August 2017, due to delay in the divestment of AstraZeneca's global rights to Meronem.

In August 2016, Astrazeneca had announced the termination of distribution arrangement by AstraZeneca UK for Meronem in India, pursuant to a global agreement by AstraZeneca PLC to sell the development and commercialisation rights to Pfizer Inc., of its late stage small molecule antibiotics business.

Further in December 2016, the validity period of the distribution agreement was extended till 31 July 2017, due to delay in the divestment of AstraZeneca's global rights to Meronem.

Powered by Capital Market - Live News

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 8 August 2017, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2017.

Powered by Capital Market - Live News